Research ExplorerPublicationsPreclinical models to study patient-derived circulating tumo...

Preclinical models to study patient-derived circulating tumor cells and metastasis

Standard

Preclinical models to study patient-derived circulating tumor cells and metastasis. / Suvilesh, Kanve N; Manjunath, Yariswamy; Pantel, Klaus; Kaifi, Jussuf T.

In: TRENDS CANCER, Vol. 9, No. 4, 04.2023, p. 355-371.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Suvilesh, KN, Manjunath, Y, Pantel, K & Kaifi, JT 2023, 'Preclinical models to study patient-derived circulating tumor cells and metastasis', TRENDS CANCER, vol. 9, no. 4, pp. 355-371. https://doi.org/10.1016/j.trecan.2023.01.004

APA

Suvilesh, K. N., Manjunath, Y., Pantel, K., & Kaifi, J. T. (2023). Preclinical models to study patient-derived circulating tumor cells and metastasis. TRENDS CANCER, 9(4), 355-371. https://doi.org/10.1016/j.trecan.2023.01.004

Vancouver

Suvilesh KN, Manjunath Y, Pantel K, Kaifi JT. Preclinical models to study patient-derived circulating tumor cells and metastasis. TRENDS CANCER. 2023 Apr;9(4):355-371. https://doi.org/10.1016/j.trecan.2023.01.004

Bibtex

@article{4fd9544fdd024584aab28a173c0d5824,
title = "Preclinical models to study patient-derived circulating tumor cells and metastasis",
abstract = "Circulating tumor cells (CTCs) that are detached from the tumor can be precursors of metastasis. The majority of studies focus on enumeration of CTCs from patient blood to predict recurrence and therapy outcomes. Very few studies have managed to expand CTCs to investigate their functional dynamics with respect to genetic changes, tumorigenic potential, and response to drug treatment. A growing amount of evidence based on successful CTC expansion has revealed novel therapeutic targets that are associated with the process of metastasis. In this review, we summarize the successes, challenges, and limitations that collectively contribute to the better understanding of metastasis using patient-derived CTCs as blood-borne seeds of metastasis. The roadblocks and future avenues to move CTC-based scientific discoveries forward are also discussed.",
author = "Suvilesh, {Kanve N} and Yariswamy Manjunath and Klaus Pantel and Kaifi, {Jussuf T}",
note = "Published by Elsevier Inc.",
year = "2023",
month = apr,
doi = "10.1016/j.trecan.2023.01.004",
language = "English",
volume = "9",
pages = "355--371",
journal = "TRENDS CANCER",
issn = "2405-8025",
publisher = "Cell Press",
number = "4",

}

RIS

TY - JOUR

T1 - Preclinical models to study patient-derived circulating tumor cells and metastasis

AU - Suvilesh, Kanve N

AU - Manjunath, Yariswamy

AU - Pantel, Klaus

AU - Kaifi, Jussuf T

N1 - Published by Elsevier Inc.

PY - 2023/4

Y1 - 2023/4

N2 - Circulating tumor cells (CTCs) that are detached from the tumor can be precursors of metastasis. The majority of studies focus on enumeration of CTCs from patient blood to predict recurrence and therapy outcomes. Very few studies have managed to expand CTCs to investigate their functional dynamics with respect to genetic changes, tumorigenic potential, and response to drug treatment. A growing amount of evidence based on successful CTC expansion has revealed novel therapeutic targets that are associated with the process of metastasis. In this review, we summarize the successes, challenges, and limitations that collectively contribute to the better understanding of metastasis using patient-derived CTCs as blood-borne seeds of metastasis. The roadblocks and future avenues to move CTC-based scientific discoveries forward are also discussed.

AB - Circulating tumor cells (CTCs) that are detached from the tumor can be precursors of metastasis. The majority of studies focus on enumeration of CTCs from patient blood to predict recurrence and therapy outcomes. Very few studies have managed to expand CTCs to investigate their functional dynamics with respect to genetic changes, tumorigenic potential, and response to drug treatment. A growing amount of evidence based on successful CTC expansion has revealed novel therapeutic targets that are associated with the process of metastasis. In this review, we summarize the successes, challenges, and limitations that collectively contribute to the better understanding of metastasis using patient-derived CTCs as blood-borne seeds of metastasis. The roadblocks and future avenues to move CTC-based scientific discoveries forward are also discussed.

U2 - 10.1016/j.trecan.2023.01.004

DO - 10.1016/j.trecan.2023.01.004

M3 - SCORING: Review article

C2 - 36759267

VL - 9

SP - 355

EP - 371

JO - TRENDS CANCER

JF - TRENDS CANCER

SN - 2405-8025

IS - 4

ER -